CodeMap®  150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax

2020 Printed Publications Early Bird Sale on Now through August 30, 2019!

User Information

Create New Account

Lost Password


Quick Links

PLA Codes

Laboratory Fee Schedule


Physician Fee Schedule


OPPS Fee Schedule


ASC Fee Schedule


APC Codes


DRG Codes


ASP Drug Pricing Files

April 2019
January 2019

CMS Transmittals

National Coverage Determination
Procedure Code: 8XXXX
Prostate Specific Antigen
CMS Policy Number: 190.31
Back to NCD List

Description: Prostate Specific Antigen (PSA), a tumor marker for adenocarcinoma of the prostate, can predict residual tumor in the post-operative phase of prostate cancer. Three to 6 months after radical prostatectomy, PSA is reported to provide a sensitive indicator of persistent disease. Six months following introduction of antiandrogen therapy, PSA is reported of distinguishing patients with favorable response from those in whom limited response is anticipated.

PSA when used in conjunction with other prostate cancer tests, such as digital rectal examination, may assist in the decision-making process for diagnosing prostate cancer. PSA also, serves as a marker in following the progress of most prostate tumors once a diagnosis has been established. This test is also an aid in the management of prostate cancer patients and in detecting metastatic or persistent disease in patients following treatment.

PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs & symptoms (e.g., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia & incontinence) as well as with patients with palpably abnormal prostate glands on physician exam, and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate disorder. PSA is also a marker used to follow the progress of prostate cancer once a diagnosis has been established, such as detecting metastatic or persistent disease in patients who may require additional treatment. PSA testing may also be useful in the differential diagnosis of men presenting with as yet undiagnosed disseminated metastatic disease.

Generally, for patients with lower urinary tract signs or symptoms, the test is performed only once per year unless there is a change in the patient’s medical condition.

Testing with a diagnosis of in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once.

Frequency Limitations: For patients with lower urinary tract signs or symptoms, total PSA is performed only once per year unless there is a change in the patient's medical condition. Medicare covers a screening total PSA test one each year for men over 50 years of age.

To review all requirements of this policy, please see: CMS NCD listing by Chapter

Covered ICD-10 Codes.

C61 Malignant neoplasm of prostate
C67.5 Malignant neoplasm of bladder neck
C77.4 Sec and unsp malig neoplasm of inguinal and lower limb nodes
C77.5 Secondary and unsp malignant neoplasm of intrapelv nodes
C77.8 Sec and unsp malig neoplasm of nodes of multiple regions
C79.51 Secondary malignant neoplasm of bone
C79.52 Secondary malignant neoplasm of bone marrow
C79.82 Secondary malignant neoplasm of genital organs
D07.5 Carcinoma in situ of prostate
D40.0 Neoplasm of uncertain behavior of prostate
D49.511 Neoplasm of unspecified behavior of right kidney
D49.512 Neoplasm of unspecified behavior of left kidney
D49.519 Neoplasm of unspecified behavior of unspecified kidney
D49.59 Neoplasm of unspecified behavior of other GU organ
M33.03 Juvenile dermatomyositis without myopathy
M33.13 Other dermatomyositis without myopathy
M33.93 Dermatopolymyositis, unspecified without myopathy
N13.9 Obstructive and reflux uropathy, unspecified
N32.0 Bladder-neck obstruction
N40.0 Benign prostatic hyperplasia without lower urinry tract symp
N40.1 Benign prostatic hyperplasia with lower urinary tract symp
N40.2 Nodular prostate without lower urinary tract symptoms
N40.3 Nodular prostate with lower urinary tract symptoms
N41.9 Inflammatory disease of prostate, unspecified
N42.9 Disorder of prostate, unspecified
R31.0 Gross hematuria
R31.1 Benign essential microscopic hematuria
R31.21 Asymptomatic microscopic hematuria
R31.29 Other microscopic hematuria
R31.9 Hematuria, unspecified
R32 Unspecified urinary incontinence
R33.9 Retention of urine, unspecified
R35.0 Frequency of micturition
R35.1 Nocturia
R39.11 Hesitancy of micturition
R39.12 Poor urinary stream
R39.14 Feeling of incomplete bladder emptying
R39.15 Urgency of urination
R39.16 Straining to void
R93.5 Abn findings on dx imaging of abd regions, inc retroperiton
R93.6 Abnormal findings on diagnostic imaging of limbs
R93.7 Abnormal findings on diagnostic imaging of prt ms sys
R94.8 Abnormal results of function studies of organs and systems
R97.20 Elevated prostate specific antigen [PSA]
R97.21 Rising PSA fol treatment for malignant neoplasm of prostate
Z85.46 Personal history of malignant neoplasm of prostate

The content and format of the following files and/or webpages are copywritten and the property of Wheaton Partners, LLC - dba CodeMap®. All recipients of these files agree not to distribute, reproduce and/or use the information contained within, in any manner not expressly agreed upon by the user and Wheaton Partners, LLC - dba CodeMap®.

All code-pairs and Medicare coverage information are compiled directly from Center for Medicare and Medicaid Services (CMS) and Medicare Contractor coverage policies. CodeMap® has made every reasonable effort to ensure the accuracy of the information contained. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. Both CMS and Medicare contractor coverage policy information may change at any time. CodeMap® makes no representation, warranty, or guarantee that this compilation of coverage policy information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

CodeMap® is a Registered Trademark of Wheaton Partners, LLC.